Home › Research › Treatments
Novel Monoclonal Antibodies for the Treatment of Alzheimers Disease using KISUNLA Drug
Vaishnavi Pravin Titare, Mrs. Sneha K. Salve, M. D. Kitukale. International Journal of Advanced Research in Science Communication and Technology, 2025-01-24
Topic: Amyloid, tau and blood-test diagnosis
For persons with early-stage sympathetic Alzheimer's disease (AD), including those with mild cognitive impairment and mild congitive dementia stages of the disease with confirmed amyloid pathology, KISUNLA (donanemab-azbt) is a disease-modifying treatment. Nearly half of research participants finished their course of treatment with Kisunla within a year, making it the first and only amyloid plaque targeting medication that uses a limited duration treatment regimen based on amyloid plaque elimination. For those with early-stage sympathetic Alzheimer's disease who desperately require an efficient therapeutic alternative, Kisunla shows extremely significant results
Key findings
- For those with early-stage sympathetic Alzheimer's disease who desperately require an efficient therapeutic alternative, Kisunla shows extremely significant results
Why it matters
Kisunla (donanemab-azbt) is described as a disease-modifying treatment for people with early-stage Alzheimer disease with confirmed amyloid pathology, and nearly half of research participants finished treatment within a year. The text claims extremely significant results but provides no specific outcome data.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 25 of the 97 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International Journal of Advanced Research in Science Communication and Technology) |
| Journal's citation record | 0 / 4 | International Journal of Advanced Research in Science Communication and Technology: journal h-index 30 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author M. D. Kitukale: h-index 2 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 25 of the 97 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.48175/ijarsct-23077
- Original source →
- Free full text: International Journal of Advanced Research in Science Communication and Technology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Titare, V. P., Salve, M. S. K., & Kitukale, M. D. (2025). Novel Monoclonal Antibodies for the Treatment of Alzheimers Disease using KISUNLA Drug. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-23077
Vancouver
Titare VP, Salve MSK, Kitukale MD. Novel Monoclonal Antibodies for the Treatment of Alzheimers Disease using KISUNLA Drug. International Journal of Advanced Research in Science Communication and Technology. 2025. doi:10.48175/ijarsct-23077.
BibTeX
@article{titare2025-4e2f63cd,
author = {Titare, Vaishnavi Pravin and Salve, Mrs. Sneha K. and Kitukale, M. D.},
title = {{Novel Monoclonal Antibodies for the Treatment of Alzheimers Disease using KISUNLA Drug}},
journal = {International Journal of Advanced Research in Science Communication and Technology},
year = {2025},
doi = {10.48175/ijarsct-23077},
url = {https://doi.org/10.48175/ijarsct-23077}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.